Merck & Co., Inc.
Mega Cap · Healthcare · Drug Manufacturers - General
$135.86+$0.31 (+0.23%)
Merck & Co., Inc.
Mega Cap · Healthcare · Drug Manufacturers - General
$135.86+$0.31 (+0.23%)
Stock analysis
Get the AI take on MRK
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$77.53
High$135.05
Today $135.86
RSI (14)
68.7Neutral
03070100
Overall score
53/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$105
Current price
$135.86
Median target
$141.5
Highest
$155
LowHigh
Operating Record
Revenue
What's working
- Forward P/E: Investors aren't pricing in much earnings growth, so there's room to be pleasantly surprised.
- ROE: Shareholder capital is compounding at a rate worth paying attention to.
What to watch
- Debt exceeds cash by $46.8B, increasing balance-sheet pressure, a warning sign.
What the market charges
Forward P/E
Favorable · 28% below avg
15.76x
Price / sales
Reasonable · Priced reasonably against its revenue
5.03x
Price / FCF
Reasonable · Priced a bit rich against its cash flow
20.86x
EV / EBITDA
Reasonable · Operating earnings make this price a stretch but plausible
13.23x
How efficiently it compounds
ROIC
Reasonable · A middling return on the capital it puts to work
14.1%
ROE
Favorable · 19.0% - strong capital efficiency
7.0%
Debt / equity
Middle ground · Mixed
1.28x
Current ratio
Reasonable · Just enough on hand to cover near-term bills
1.32x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $335.14B | 108.6 | +4.6% | 53 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |
What is moving MRK
News
- 2d ago · Merck & Co., Inc. via Yahoo Finance
Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine
Bullish - 2d ago · Merck & Co., Inc. via Yahoo Finance
Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress
Bullish - 2d ago · Merck & Co., Inc. via Yahoo Finance
Merck (MRK) Stock Looks Fully Valued Following Raised Revenue Outlook
Bearish